# Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

> **NCT02415959** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 70 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis

## Interventions

- **DRUG:** Creon IR
- **DRUG:** Creon® (DR/GR)

## Key facts

- **NCT ID:** NCT02415959
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415959, "Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02415959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*